Fig. 6
EGFRxHER2 T-BsAbs efficacy is lost in EGFR and HER2-single-positive PDAC (A) Mean fluorescent intensities determined by flow cytometry and (B) antibody-dependent T cell-mediated cytotoxicity (ADTC) against SW1990-EGFR-KO (left) and SW1990-HER2-KO (right) cell lines. Ratio of effector T cells to target PDAC cells (E: T ratio) was set to 10:1. (C) Tumor growth of subcutaneous SW1990 EGFR-KO (left) and HER2-KO (right) tumors. One infusion of 2 × 107 T cells was administered. Two doses of T-BsAbs (10 µg each) were given by i.v. injection